Phase 2CompletedAge-related condition
QA102 Phase II Study in Subjects With Dry AMD (AMEND)
A Phase 2, Double-Masked, Randomized, Placebo-Controlled, Dose-Response Study Assessing the Safety and Efficacy of QA102 in Subjects With Dry Age-Related Macular Degeneration (AMD)
- Sponsor
- Smilebiotek Zhuhai Limited (Industry)
- Enrolment
- 150 enrolled
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- QA102/Placebo; QA102; Placebo
- Ages
- adults, older adults
- Registry
- NCT05536752
Full record on ClinicalTrials.gov
From the registry
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Primary outcomes
- Change From Baseline in Soft Drusen Volume (mm3)
History
Results first posted
Last registry update
Primary completion
Started
Registered